Go to Samples

Eli Lilly and Co.
Trulicity Demo Pen
Trulicity Autoinjector Demo Pen Kit
Indications and Usage
TRULICITY® is indicated:
- As an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes mellitus.
- To reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) in adults with type 2 diabetes mellitus who have established cardiovascular disease or multiple cardiovascular risk factors.
Limitations of Use
TRULICITY:
- Has not been studied in patients with a history of pancreatitis [see Warnings and Precautions ]. Consider other antidiabetic therapies in patients with a history of pancreatitis.
- Should not be used in patients with type 1 diabetes mellitus.
- Has not been studied in patients with severe gastrointestinal disease, including severe gastroparesis and is therefore not recommended in these patients [see Warnings and Precautions ].
More than 200,000 clinicians have integrated PrescriberPoint into their clinical workflows















HOW IT WORKS
The easy way to access samples
Confirm EligibilitySamples are available for authorized US healthcare providers
Create Free AccountRequest, track, and manage samples from multiple brands
Get your SampleSamples shipped directly to your practice door
Want to check your eligibility to order samples?
WHO IS PRESCRIBERPOINT
Increasing patient access to medications they need
At PrescriberPoint, we're revolutionizing how healthcare providers get patients the medications they need. We craft solutions that help providers address the challenges in patient access and improve outcomes.200K+Visitors Each Month
100K+Engagements Each Month
1M+Resources Viewed
WHAT HCPS ARE SAYING
FAQs
All you need to know to order samples
Currently, PrescriberPoint is available only in the U.S, but we are excited to expand our reach in the future! Stay connected by following us or signing up for our newsletter to get the latest updates, including announcements about new market launches.